Sort
48,018 grants matching “immunotherapy”
PROTEAN-CR: Proteomics Toolkit for Ensemble Analysis in Cancer Research
$397,442Lydia E. Kavraki · Rice University · U01 · FY2022 · CA
Vaccines, Immunoprophylaxis, and Immunotherapy for SARS
$397,437Kanta Subbarao · National Institute Of Allergy And Infectious Diseases · ZIA · FY2011 · AI
Designing Antibody Drug Conjugates for Durable and Complete Therapeutic Responses
$397,428Greg Thurber · University Of Michigan At Ann Arbor · R35 · FY2025 · GM
MyD88 fusion protein with antigen specific T Cell therapy for enhanced response in solid tumors
$397,422Samantha Dunmire · Luminary Therapeutics, Inc. · R43 · FY2020 · CA
T. forsythia TLR2 ligands and surface glycans coordinate periodontal inflammation
$397,417Ashu Sharma · State University Of New York At Buffalo · R01 · FY2017 · DE
The Inhibition of HNSCC Growth and Metastasis by Targeting KDM4A
$397,373Cun-Yu Wang · University Of California Los Angeles · R01 · FY2021 · DE
The Inhibition of HNSCC Growth and Metastasis by Targeting KDM4A
$397,371Cun-Yu Wang · University Of California Los Angeles · R01 · FY2023 · DE
Silencing of HIV-1 proviruses by epigenetically targeting transcriptional elongation
$397,273Qin Feng · University Of Houston · R61 · FY2018 · AI
Cell lineage as an indicator of immune response in neuroblastoma
$397,270Rani E George · Dana-Farber Cancer Inst · R01 · FY2023 · CA
DEVELOPMENTAL FUNDS (Core-002)
$397,212Beverly Shriver Mitchell · Stanford University · P30 · FY2016 · CA
BOSTON AIDS MALIGNANCY CONSORTIUM
$397,171Massachusetts General Hospital · U01 · FY2001 · CA
Regulation of RNA Decapping and Degradation: A novel approach to prostate cancer therapy
$397,168Andrew S Kraft · Vortex Biotechnology Corporation · R43 · FY2023 · CA
TLR5 signaling as a conserved mechanism of impaired anti-tumor immunity
$397,110Melanie R Rutkowski · University Of Virginia · R01 · FY2024 · CA
Cancer Cell Intrinsic Interferon-I pathway Activation by Fractionated Radiation
$397,076Sandra Demaria · Weill Medical Coll Of Cornell Univ · R01 · FY2023 · CA
Optimizing pre-analytic sample handling for high throughput TCR sequencing in cutaneous T cell lymphoma
$397,067Rachael Ann Clark · Brigham And Women'S Hospital · U01 · FY2023 · CA
Optimizing pre-analytic sample handling for high throughput TCR sequencing in cutaneous T cell lymphoma
$397,067Rachael Ann Clark · Brigham And Women'S Hospital · U01 · FY2022 · CA
Identifying Therapeutic Targets for Stage III Melanoma
$397,059Anand K Ganesan · University Of California-Irvine · R01 · FY2024 · CA
Subcellular enzyme-instructed self-assembly for molecular anticancer nanomedicines
$397,052Bing Xu · Brandeis University · R01 · FY2025 · CA
Subcellular enzyme-instructed self-assembly for molecular anticancer nanomedicines
$397,052Bing Xu · Brandeis University · R01 · FY2023 · CA
Mechanisms of liver metastasis and associated resistance to immunotherapy
$397,013Benjamin Izar · Columbia University Health Sciences · R37 · FY2023 · CA
Systemic delivery of an oncolytic adenovirus targeting TGFβ to enhance anti-PD-1 and anti-CTLA-4 therapy for triple negative breast cancer
$396,958Weidong Xu · Endeavor Health Clinical Operations · R01 · FY2024 · CA
MULTI-EPITOPE MELANOMA VACCINES FOR CD4 AND CD8 T-CELLS
$396,912Craig Lee Slingluff · University Of Virginia · R01 · FY2009 · CA
A Precision Medicine Tool for Optimal Personalized Treatment in Patients with Acute Myeloid Leukemia
$396,908Athanasios Mantalaris · Sanicka, Inc · R42 · FY2022 · CA
Induction of interferon response by chromatin damaging anti-cancer therapy
$396,881Katerina V Gurova · Roswell Park Cancer Institute Corp · R01 · FY2025 · CA
Induction of interferon response by chromatin damaging anti-cancer therapy
$396,881Katerina V Gurova · Roswell Park Cancer Institute Corp · R01 · FY2024 · CA